Skip to main content

NPPA notify pharma companies to maintain adequate stock of swine flu drugs

Due to increasing cases of swine flu in India, it was came to know that swine flu drugs are running short in stock. Therefore, National Pharmaceutical Pricing Authority (NPPA) asks pharma companies to maintain adequate amount of swine flu drug in the country to ensure a smooth supply of medicines.

NPPA received reports that the medicines used for swine flu, Oseltamivir, Zanamivir, Rimantadine are in short supply in the countryand the non-availability of these vital drugs may lead to high risk of complications to the patients infected with H1N1 virus.

So, NPPA requested to pharma companies like Cipla, Hetero Lab, Strides Acrolab, Ranbaxy and other companies which are involved in manufacturing of swine flu drugs to maintain adequate stock and to ensure smooth supply of the drugs for providing relief to the patients affected with swine influenza virus.

NPPA also advised them to rush the stock immediately wherever short supply is reported in the country.

NPPA notified to the manufacturers of Swine flu drugs that they are required to submit the stock and supply position, drug wise, on monthly basis.

<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>

Search this website